Alexandra Drakaki is an MD, PhD, and Associate Professor of Hematology/Oncology and Urology. She received her training in Internal Medicine as part of a Tuft's University affiliate program, while she completed her Hematology / Oncology training at Beth Israel Deaconess Medical Center at Harvard Medical School and her research fellowship at Dana Farber Cancer Center Harvard Medical School in Boston. She specializes in Genitourinary cancers and specifically cancers of the Bladder, Kidney, Prostate and Testicles. She is the Primary Investigator in therapeutic clinical trials as well as the Lead Investigator at a national level in studies that are testing novel drugs. Her research interest is studying the role of a class of genes, named non-coding RNAs, including microRNAs and linkRNAs in genitourinary malignancies. She also has a special interest in studying and understanding the mechanism of drug-related toxicity to find combinations of medications that reverse/prevent toxicity without stopping effective therapies. She is part of the Translational Oncology Research Laboratory of the globally renowned Dr. Slamon, in which researchers are working on drug development by using novel technologies for breakthrough discoveries to treat cancer.